Sugi Predict

Sugi Predict / Compounds / SCHEMBL304843

SCHEMBL304843

SCHEMBL304843

[CH2]c1ccc(C(N)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.55
▸ TSHR P16473 2/20 0.55
▸ POLB P06746 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ RECQL P46063 1/20 0.55
▸ BLM P54132 1/20 0.55
▸ PMP22 Q01453 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ PARP10 Q53GL7 10/20 0.54
▸ PARP4 Q9UKK3 2/20 0.54
▸ PARP15 Q460N3 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ PARP14 Q460N5 1/20 0.54
▸ PARP16 Q8N5Y8 1/20 0.54
▸ PARP11 Q9NR21 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29059675 0.93 CA2 (0.55) PARP1TSHRPOLBCYP3A4MAPT
Terephthalamide SCHEMBL15168441 0.85 PARP1 (0.63) PARP1TSHRPOLBCYP3A4MAPT
Terephthalamide SCHEMBL538997 0.85 PARP1 (0.63) PARP1TSHRPOLBCYP3A4MAPT
Terephthalamide SCHEMBL23774 0.85 PARP1 (0.71) PARP1TSHRPOLBCYP3A4MAPT
Terephthalamide SCHEMBL1906838 0.82 PARP1 (0.67) PARP1TSHRPOLBCYP3A4MAPT
Terephthalamide SCHEMBL11512422 0.82 PARP1 (0.67) PARP1TSHRPOLBCYP3A4MAPT
Terephthalamide SCHEMBL7508927 0.82 PARP1 (0.67) PARP1TSHRPOLBCYP3A4MAPT
Terephthalamide SCHEMBL1087289 0.82 PARP1 (0.67) PARP1TSHRPOLBCYP3A4MAPT
Terephthalamide SCHEMBL689841 0.82 PARP1 (0.67) PARP1TSHRPOLBCYP3A4MAPT
Terephthalamide SCHEMBL15328883 0.82 PARP1 (0.67) PARP1TSHRPOLBCYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240218022-A1 ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-04 — — US claimed
US-20230192657-A1 1,2,4-TRIAZOLINONE CB1 INHIBITORS GFB (ABC), LLC 2023-06-22 — — US claimed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 — — US claimed
EP-4114838-A1 1,2,4-TRIAZOLINONE CB1 INHIBITORS Goldfinch Bio, Inc. (US) 2023-01-11 — — EP claimed
EP-4100410-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE Neurocrine Biosciences, Inc. (US) 2022-12-14 — — EP claimed
CN-115362156-A Muscarinic receptor 4 antagonists and methods of use 纽罗克里生物科学有限公司 2022-11-18 — — CN claimed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 — — WO claimed
WO-2021062089-A1 XANTHINE CB1 INHIBITORS GOLDFINCH BIO, INC. (US) 2021-04-01 — — WO claimed
US-20190031618-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-01-31 — — US claimed
EP-2629777-B1 BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME (US) 2018-12-19 — — EP claimed
EP-1988076-A1 AMIDE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-05 — — EP claimed
US-20080269225-A1 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-10-30 — — US claimed
EP-1976528-A2 PROKINETICIN 2 RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2008-10-08 — — EP claimed
WO-2008012227-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-31 — — WO claimed
US-20080021032-A1 Pyrazole glucokinase activators BERTHEL STEVEN JOSEPH 2008-01-24 — — US claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 — — WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 — — US claimed
WO-2007079214-A2 PROKINETICIN 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-12 — — WO claimed
US-4831041-A ANTIULCER AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-05-16 — — US claimed
EP-0268989-A1 Imidazopyridine compounds and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-06-01 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031618-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS CNR1, GPR119, CNR2 PARP1 2835/4885TSHR 777/4885POLB 3443/4885
US-20240218022-A1 ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS VIP, SGTA, NGLY1 PARP1 2194/4885TSHR 459/4885POLB 3496/4885
US-20080269225-A1 Prokineticin 1 receptor antagonists PROKR1, PROKR2, GIPR PARP1 1984/4885TSHR 228/4885POLB 3963/4885
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 PARP1 2709/4885TSHR 1287/4885POLB 2841/4885
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 PARP1 4745/4885TSHR 131/4885POLB 4490/4885
US-20230192657-A1 1,2,4-TRIAZOLINONE CB1 INHIBITORS CNR1, GPR119, CNR2 PARP1 1288/4885TSHR 2373/4885POLB 4633/4885
US-20080021032-A1 Pyrazole glucokinase activators GCKR, GCK, GALK1 PARP1 3548/4885TSHR 2577/4885POLB 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.